An orally bioavailable spleen tyrosine kinase inhibitor delays disease progression and prolongs survival in murine lupus

Abstract

We demonstrate that a novel Syk-selective inhibitor prevents the development of renal disease and treats established murine lupus nephritis. These data suggest that Syk inhibitors may be of therapeutic benefit in human lupus and related disorders.